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Cellular retinaldehyde binding protein (CRALBP) is an autoantigen in spontaneous equine recurrent uveitis. In order to test
whether CRALBP contributes to human autoimmune uveitis, the speciﬁcity of antibodies from human uveitis patient’s sera was
ﬁrst evaluated in two-dimensional (2D) Western blot analysis. Subsequent identiﬁcation of the immunoreactive proteins by mass
spectrometryresultedintheidentiﬁcationofCRALBPasaputativeautoantigen.Additionally,serafromhumanuveitisandcontrol
patients were by Western blot using puriﬁed human recombinant CRALBP. Anti-CRALBP autoantibodies occur more frequently
(P<. 01) in human uveitis patients than in normal controls. Thirty out of 56 tested uveitis patient’s sera contained autoantibodies
reactive against CRALBP, compared to only four out of 23 normal control subjects. The presence of CRALBP autoantibodies in
54% of tested uveitis patients supports CRALBP as a possible autoantigen in human autoimmune uveitis.
Copyright © 2007 Cornelia A. Deeg et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Cellular retinaldehyde binding protein (CRALBP) was re-
cently detected as major autoantigen in equine recurrent
uveitis (ERU), a spontaneous model of human uveitis [1].
Similarly to the two other major uveitis autoantigens, S-
antigen (S-Ag) [2], and interphotoreceptor retinoid binding
protein (IRBP) [3], CRALBP is expressed in both the retina
and the pineal gland. CRALBP is a key component of the
retinoid visual cycle and participates in the regeneration of
11-cis-retinalafterphotoisomerization[4].Theproteinisex-
pressedabundantlyinRPEcells,wheremanyreactionsofthe
rodvisualcycletakeplace.Additionally,itisfoundinMueller
glialcells,whichhavebeenimplicatedinconevisualpigment
regeneration [4]. In addition to the RPE and Mueller glial
cells of the retina, CRALBP expression has been reported in
the ciliary body, cornea, pineal gland, optic nerve, brain, and
the iris [4]. While ligands in nonretinal tissues have yet to be
identiﬁed [4], the protein interacts in the retina with several
proteins supporting retinoid supply and participating in the
visualcycle[5].MutationsintheCRALBPgenehavebeenas-
sociated with several autosomal recessive retinal pathologies,
including retinitis pigmentosa, retinitis punctata albescens,
bothnia dystrophy, fundus albipunctatus, and in the new-
foundland rod/cone dystrophy [4, 6].
Recently, CRALBP was identiﬁed as a novel autoanti-
gen in a spontaneous horse disease (ERU), which serves as
a model for human autoimmune uveitis. Subsequent char-
acterization of ERU cases revealed B- and T-cell autoreactiv-
ity to CRALBP and established a link to epitope spreading
[1]. Immunization of experimental animals with CRALBP
induced uveitis in two diﬀerent species with typical tissue
lesions at CRALBP-expression sites. ERU shares with hu-
man uveitis [7, 8] the autoimmune response to at least two2 Clinical and Developmental Immunology
diﬀerent autoantigens, S-Ag and IRBP. The aim of this study
was to investigate the immune response of human uveitis pa-
tients to the potential autoantigen CRALBP.
2. MATERIALS AND METHODS
2.1. Bloodsamplesanddonoreyes
Sixnormalhumandonoreyeswithnoclinicalsignsofuveitis
(2 female, 4 male; mean age 46 years) were used for evalu-
ation of CRALBP expression pattern in normal eyes. Sam-
pling was approved by the local ethics committee in compli-
ancewiththetenetsofthedeclarationofHelsinki.Alldonors
gave their informed consent. Peripheral blood samples of 56
patients (34 male, 22 female; mean age 36 years; white Eu-
ropeans) with uveitis and 23 eye-healthy control subjects (7
male, 16 female; mean age 34 years; white Europeans) were
usedforthisstudy.Uveitisinpatientswasdeﬁnedbyintraoc-
ular inﬂammatory signs like endothelial precipitates, cells,
andhazeinanteriorchamberand/orvitreousorsignsofreti-
nal vasculitis and choroidal or retinal inﬁltrates.
After collection of blood, samples were processed imme-
diately and either serum or plasma was stored at −20◦C until
Western blots were performed. Donor eyes were ﬁxed 15–60
hours postmortem in 6% buﬀered formalin.
2.2. Expressionandpuriﬁcationofhuman
recombinantCRALBP
Human recombinant CRALBP was expressed in E. coli (In-
vitrogen, Karlsruhe, Germany) and puriﬁed on a Nickel
agarose column (Qiagen, Hilden, Germany) [9]. Endotoxin
was removed on an Endotrap red column (Profos, Regens-
burg, Germany) and then controlled by a Limulus amebo-
cyte lysate test (Sigma, Deisenhofen, Germany; levels below
0.8EU/mL). The identity of puriﬁed recombinant CRALBP
w a sc o n ﬁ r m e db ym a s ss p e c t r o m e t r y .
2.3. Histologyandimmunostaining
Formalin ﬁxed eyes were embedded in Paraﬃn( M i c r o m ,
Walldorf, Germany). Antigen retrieval was performed at
99◦Cf o r1 5m i n u t e si n0 .1M EDTA–NaOH buﬀer pH 8.8.
We used rabbit anti-human Glial ﬁbrillary acidic protein
(GFAP; 1:100, Sigma) antiserum to stain Mueller glial cells
and horse anti-human recombinant CRALBP antiserum
(1:500) to evaluate CRALBP expression in normal human
donoreyes.Forﬂuorescencelabeling,GFAPwasstainedwith
an anti-rabbit IgG antibody coupled to Alexa 568 (1:500, In-
vitrogen)andCRALBPwithanantihorseIgG-FITCantibody
(1:200, Sigma). Nuclei were counterstained with DAPI (In-
vitrogen).
2.4. Two-dimensional(2D)Westernblotting
Fresh equine retinas were immediately stabilized with a pro-
tease inhibitor (Complete, Roche, Penzberg, Germany), ho-
mogenized, lyophilized, and stored at −80◦C. For 2D anal-
ysis, protein pellets were solubilized in 2D lysis buﬀer (9M
urea, 2M thiourea, 1% DTE, 4% CHAPS). Immobiline dry
strips pH 3–11NL, 11cm (GE-Healthcare, Freiburg, Ger-
many) were immersed overnight in lysis buﬀer containing
75μg protein sample, additional 1% pharmalytes pH 3–10
(GE-Healthcare), and 0.5% bromphenole blue. Isoelectric
focusing was performed on a Multiphor (GE-Healthcare)
for 15kVh at 20◦C, followed by separation on gradient
SDS-PAGE gels (9–15%) at constant 45V per gel. One
set of gels was silver-stained for mass spectrometry and
the second transferred onto nitrocellulose membranes (GE-
Healthcare) for Western blot analysis. Nitrocellulose mem-
branes were blocked with 1% PVP in PBS-T (1hour) and
incubated with sera from uveitis patients and controls (dilu-
tion 1:500; overnight at 4◦C). Autoantibody binding was de-
tected using rabbit anti-human-IgG-HRP (1:4000, 1h; Bio-
zol, Eching, Germany) and enhanced chemiluminescence
(GE-Healthcare). To assign visible spots to those detected
on silver-stained gels, we subsequently stained the nitrocel-
lulose membranes with colloidal gold (Fluka, Deisenhofen,
Germany).
2.5. 1DWesternblotsfordetectionofanti-CRALBP
autoantibodies
Puriﬁed and LPS-free human recombinant CRALBP (1μg
protein per lane) was applied to 10% sodium SDS-PAGE
and blotted semidry onto nitrocellulose membranes. Non-
speciﬁc binding was blocked with 1% PVP in PBS-T (1h).
Blots were subsequently incubated with sera in PBS-T (di-
lution 1:500; overnight at 4◦C) washed and then incubated
with horseradish peroxidase-conjugated secondary antibody
(1:4000; 1hour, rabbit anti-human-IgG-HRP; Biozol). Sig-
nals were then detected with ECL (enhanced chemilumi-
nescence) on Hyperﬁlm ECL (GE Healthcare) according
to manufacturer’s instructions. A monoclonal anti-human
CRALBP antibody (0.02μg/mL; Cayman, Tallinn, Estonia)
was used as a positive control.
2.6. Imageanalysisandquantiﬁcationofsignals
Quantiﬁcation of Western blot signals was performed by
densitometry with ImageQuant TL software (GE Health-
care) after scanning the ﬁlms on a transmission scanner (Im-
ageScanner II, GE Healthcare). Images of blot signals on x-
ray ﬁlms (8bit/600dpi resolution) were imported to analysis
software (Image Quant TL, v2003) and band volume inten-
sities were quantiﬁed.
2.7. Statisticalsigniﬁcance
The statistical signiﬁcance of the frequency of CRALBP au-
toantibodies in uveitis and control groups was evaluated us-
ing the chi-square test. Intensities of positive Western blot
signals of uveitis patients and negative controls were com-
pared using the student’s t-test.Cornelia A. Deeg et al. 3
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Figure 1: Identiﬁcation of CRALBP-autoantibodies with proteomic Western blots. (a) Equine retinal proteome (pH gradient 3–11, silver stain-
ing) was separated on 2D gels and transferred to nitrocellulose membranes. (b) Serum from human uveitis patient detects CRALBP (en-
circled). CRALBP expression in normal human eyes. (c) Nomarski image of normal human retina (donor no. 6, male, age 49). (d) CRALBP
expression (green) at Mueller glial cells. (e) GFAP expression (red) at Mueller glial cells. (f) Double labeling of CRALBP (green) and GFAP
(red) clearly demonstrates colocalization (yellow) of CRALBP and GFAP at Mueller glial cells.
3. RESULTS
3.1. CRALBP:anovelhumanuveitisautoantigen
Autoantibody proﬁling led to identiﬁcation of CRALBP as a
novel uveitis autoantigen in horses with spontaneous equine
recurrent uveitis (ERU) [1]. Sera from human uveitis pa-
tients reacted with CRALBP in 2D Western blots using nor-
mal equine retinal proteome as a source of antigen (Fig-
ure 1(a), equine retinal proteome, Figure 1(b),2 DW e s t e r n
blot incubated with serum of human uveitis patient). The
equine retinal proteome was separated by 2D (Figure 1(a),
silver staining) over the pH range 3 to 11. Several hundred
proteins could be detected as discrete spots using this high-
resolution technique (Figure 1(a)). Western blot analysis us-
ing sera from human uveitis patients with posterior uveitis
followed by mass spectrometric analysis of the immunore-
active 2D gel components resulted in the identiﬁcation of
CRALBP (Figure 1(b), encircled).
3.2. CRALBPisexpressedinMuellerglialcellsand
RPEinnormalhumaneyes
Immunohistochemical staining for CRALBP in six normal
human donor eyes (Figure 1(c), Normarski image of donor
eye number 6) displayed a strong expression of CRALBP
in Mueller glial cells (Figure 1(d), green). To conﬁrm this
expression, we additionally stained for glial ﬁbrillary acidic
protein (GFAP), a class-III intermediate ﬁlament that is
Mueller glial cell-speciﬁc (Figure 1(e), red). Double stain-
ing for CRALBP (green) and GFAP (red) conﬁrmed co-
localization of both proteins in Mueller glial cells (Fig-
ure 1(f), overlay of CRALBP and GFAP expression yellow)
but also CRALBP expression in retinal pigment epithelium.4 Clinical and Developmental Immunology
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Figure 2: Representative Western blot signals at 36kD obtained
against puriﬁed human CRALBP. Sera of human uveitis patients and
healthycontrolsweretestedon1DWesternblots.Lane1:strongsig-
nal of healthy control, lane 2: healthy signal of healthy control, lanes
3 and 4: intermediate signal of uveitis patients, lane 5: healthy signal
of uveitis patient, lane 6 and 7: strong signal of uveitis patients, lane
8: monoclonal anti-human recombinant CRALBP antibody (Cay-
man), lane 9: marker with respective molecular weights.
3.3. Detectionofanti-CRALBPautoantibodiesin
seraofuveitispatients
Since access to fresh human retinal specimen for 2D experi-
ments is limited, we conﬁrmed our ﬁndings by Western blots
using puriﬁed human recombinant CRALBP as antigen. The
majority of tested patients was CRALBP-autoantibody pos-
itive, however at diﬀerent levels of signal intensities. Repre-
sentative results for intermediate, strong, and negative blot
results are shown in Figure 2 (signal at 36kD, intermediate
signals lanes 3 and 4, strong signals lanes 6 and 7, negative
signals lane 5). A few sera of healthy individuals (controls)
also contained anti-CRALBP autoantibodies (Figure 2,l a n e
1). As positive control, the puriﬁed CRALBP preparation
was also clearly recognized by a monoclonal human anti-
CRALBP antibody (Figure 2,l a n e8 ) .
3.4. Signiﬁcanthigherprevalenceofanti-CRALBP
autoantibodiesinuveitispatients
Thirty out of 56 tested uveitis patients were CRALBP
autoantibody-positive (54%) compared to four out of 23
(17%) normal control subjects (Figure 3, white circles repre-
sent individual healthy subjects, grey circles uveitis patients).
Quantiﬁcation of Western blot signals and statistical eval-
uation with student’s t-test revealed no diﬀerence in bind-
ing intensities between the positive uveitis sera compared to
autoantibody-positive sera of normal controls (Figure 3,Y -
axis:intensityofWesternblotsignalasquantiﬁedwithImage
Quant TL software). The higher prevalence of anti-CRALBP
600
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Figure 3: Frequency and intensity of human IgG autoantibodies to
CRALBP. White circles represent healthy individuals, grey circles
human uveitis patients. Western blot signal intensities were quan-
tiﬁed with Image Quant TL software, grayscale pixel intensity of
bands is given as arbitrary units (Y-axis). Negative reactions are dis-
patched below cutoﬀ line. CRALBP autoantibodies occurred signif-
icantlymorefrequentlyinuveitispatientsasincontrolgroup(com-
pared by chi-square test, signiﬁcance level < 0.01).
autoantibodies in human uveitis sera is statistically signiﬁ-
cant (P<. 01) as evaluated by the chi-square test.
4. DISCUSSION
Most autoimmune diseases display reactivity to multiple au-
toantigens [10–12].However,therelativeimportanceofeach
autoantigen for a speciﬁc disease may diﬀer considerably.
Autoantigens may appear as a consequence from tissue de-
struction and thus only represent an epiphenomenon of the
pathogenesis, for example, in T-cell-driven diseases. On the
other hand, identiﬁcation of various concurring autoanti-
gens could point to epitope spreading as a pathogenic mech-
anism in the particular disease [10]. Finally, some autoanti-
gens are useful for predicting individuals at risk for develop-
ing the respective autoimmune disease [12].
Recently, CRALBP was identiﬁed as a novel uveitis au-
t o a n t i g e ni nh o r s e su s i n ga2 DW e s t e r nb l o ta p p r o a c h[ 1].
Reactivity of sera from horses suﬀering from spontaneous
ERU included the known autoantigens S-Ag and IRBP and
two novel autoantigens, namely, recoverin and CRALBP [1].
Previously, CRALBP had been described only in association
to genetic mutations causing retinal degenerations [4, 6].
Given that CRALBP autoantibodies are present in human
uveitis sera (this study) and that CRALBP induces recur-
rent uveitis in experimental horses and rats [1], CRALBP
meets Witebsky’s postulates regarding autoantigenicity [13].
Witebskyoriginallyclaimedthreepostulationstoprovearel-
evant autoantigen. First, the target antigen must be identi-
ﬁed; second, an autoimmune reaction against this autoanti-
gen must be detectable; and third, the potential of the au-
toantigen to induce the respective disease must be proven.
Rose et al. proposed three types of evidence to qualify as the
third postulate [1]. These are direct evidence from transferCornelia A. Deeg et al. 5
of pathogenic antibody or pathogenic T cells, indirect ev-
idence based on reproduction of the autoimmune disease
in experimental animals, and circumstantial evidence from
clinical clues [13]. In view of the fact that in this study
CRALBP was recognized as an uveitis autoantigen by human
patient’s serum and speciﬁc autoantibodies were detected in
signiﬁcant amounts in cohorts of uveitis patients (Figures
1(b), 2,a n d3), the ﬁrst two of Witebsky’s postulates are ful-
ﬁlled [13]. As the uveitogenic potential of CRALBP has al-
r e a d yb e e nd e m o n s t r a t e di nt w od i ﬀerent experimental an-
imal species [1], this again meets the Witebsky’s postulates
and suggests CRALBP as a true autoantigen for human au-
toimmune uveitis, accomplishing the third postulate.
The morphological changes in the retina following
CRALBP-induced uveitis in animals show several distinct
histological features, which provide researchers familiar with
the histopathology of humanuveitis afurtheropportunity to
conﬁrm or reject CRALBP as autoantigen in humans from
clinical clues (circumstantial evidence). Immunohistochem-
ical evaluation of CRALBP expression pattern in normal hu-
man eyes conﬁrmed strong expression in Mueller glial cells
[4] through coexpression with GFAP (Figure 1(c)–1(f)). A
predominant histopathological ﬁnding in CRALBP-induced
uveitis in horses was the marked destruction of retinal ar-
chitecture with rather minor inﬁltration of inﬂammatory
cells compared to S-Ag or IRBP-induced uveitis [1]. Major
changes involved disorganization of Mueller glial cells with
fractional destruction accompanied by marked upregulation
of glial acidic ﬁbrillary protein and concurrent downregula-
tion of glutaminsynthetase [1], indicating Mueller glial cell
proliferation [14]. Additionally, overexpression of VEGF, a
major cytokine causing vascular leakage and angiogenesis,
could be demonstrated in retinal vessels and Mueller glial
cells in CRALBP-induced uveitis in rats and horses [1].
Autoimmune uveitis is a T cell-mediated disease driven
by CD4+T cells with a Th1 phenotype [15] and can be in-
duced successfully by adoptive transfer of antigen-speciﬁc
CD4+T cells and T cell lines [16, 17]. Therefore, the ability
of CRALBP to stimulate T cells of uveitis patients in vitro
should be examined. However, a recurring problem of in
vitroproliferationassaysusingperipheralbloodderivedlym-
phocytes (PBL) is that responses to autoantigens are rarely
detected [8, 18]. Predominantly weak responses to autoanti-
gens were, for example, also reported in the blood of mul-
tiple sclerosis [19] or rheumatic arthritis [20] patients. The
low frequency of antigen-speciﬁc peripheral blood lympho-
cytes even in advanced cases of uveitis has been discussed as
one reason for poor results in these proliferation assays [21].
Thishypothesisisunderlinedbyaconsiderablyincreasedfre-
quency and far stronger response of intravitreal lymphocytes
compared to PBL in ERU diseased horses [8].
Another aspect of CRALBP autoreactivity in uveitis pa-
tients and the few control subjects could focus on the predic-
tive value of this immune reaction. Recent studies in other
autoimmune diseases clearly support the potential of fore-
tellingthedevelopmentoftheautoimmunediseasewhenau-
toantibodies to a number of autoantigens are already present
in the preclinical phase [10]. Type I diabetes is one such
example and well studied. The presence of autoantibodies
against three diﬀerent diabetes autoantigens has a high pre-
dictive value for developing diabetes between 46% and 80%
in the general population, which increases to 100% in ﬁrst-
degree relatives [10, 22–24]. It has also been reported that
the autoimmune process precedes overt clinical symptoms
for many months or years [10]. Therefore, the four CRALBP
autoantibody-positive healthy subjects included in this study
will be followed on their immune response and health sta-
tus, since they could be at risk to develop uveitis in the fu-
ture. Similarly, the CRALBP autoantibody-positive healthy
control horses from the ﬁrst CRALBP detection study [1]a r e
currently monitored.
A dynamic epitope spreading cascade may exist in spon-
taneous ERU cases [25]a sw e l la si nh u m a nu v e i t i sp a t i e n t s
[7]. Evidence for the involvement of CRALBP in the spread-
ing cascade was established in ERU cases [1], and therefore
CRALBP should now also be included in future studies on
epitope spreading in human uveitis patients.
Given that CRALBP function is not fully understood to
date [26] and ligands in nonretinal tissues have yet to be
identiﬁed [4], it is not diﬃcult to assume several yet unde-
tected roles of CRALBP that could be of further interest in
association with uveitis.
5. CONCLUSIONS
Our ﬁndings suggest that CRALBP is a novel autoantigen
for human autoimmune uveitis that merits further investi-
gations.
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